Latest News

Avantium NV bags money for demo plant

© Avantium NV


by tg

Green chemistry company Avantium NV has secured a €7.5m funding from the National Programme Groningen to support the construction of a 5 kilotonnes FDCA plant.

The new grant is part of a €30m financing mix that Avantium and the Groningen consortium announced this January.

FDCA is the key building block for PEF (polyethylene furanoate), a plant-based, fully recyclable plastic material that outperforms today’s standard PET with regards to environmental footprint and performance. The FDCA flagship plant to be built in Delfzijl is planned to start up in 2023. This will provide around 60 jobs in the region. 

Avantium and the Groningen consortium already entered into an agreement earlier this year relating to the conditional financing mix of €30m for the construction of the FDCA plant.  The Groningen consortium comprises of the Province of Groningen, Groningen Seaports and regional investment funds NOM (Investment and Development Agency for the Northern Netherlands), FondsNieuweDoen, Investeringsfonds Groningen and Groeifonds.

Roche in take-over deal with GenMark Diagnostics

The US$1.8bn cash merger – US$ 24.05 per share –  is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

Novel COVID antibody enters clinical testing

In contrast to existing COVID-19 treatments, the safety design of COR-101 is optimised for the treatment of hospitalized COVID-19 patients with...

Janssen to pledge COVID-19 vaccine to African Union

The announcement follows a contract signed last year with the global vaccine alliance Gavi to deliver up to 500 million doses of JNJ’ adenoviral...

Two companies aim for 2nd-gen COVID vaccines

As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

Oxular Ltd raises US$37m

Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...

miRNAs unmask vulnerability in breast cancer stem cells

The study results, published in the Journal of Cell Biology, reveal that targeting these microRNAs sensitivies cancer stem cells to certain...

German researchers find reason for remdesivir's inefficiency

“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...